Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY

https://doi.org/10.20996/1819-6446-2012-8-4-569-572

Full Text:

Abstract

Up to date antithrombotic medications applied in patients with atrial fibrillation are discussed. Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered
in terms of efficacy and safety of alone.

About the Author

M. Yu. Gilyarov
I.M. Setchenov First Moscow State Medical University
Russian Federation


References

1. Allen C.L., Bayraktutan U. Risk factors for ischaemic stroke. Int J Stroke 2008; 3: 105–116.

2. Ferro J. Cardioembolic stroke: an update. The Lancet Neurology 2003; 2: 177–188.

3. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369–2429.

4. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med 2007; 146: 857–867.

5. Olesen J.B., Lip G.Y ., Lindhardsen J et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739–749.

6. Dahri K., Loewen P . The risk of bleeding with warfarin: A systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98: 980–987.

7. Pisters R., Lane D. A., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; Vol.

8. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139–1151.

9. Banerjee A, Lane D.A., Torp-Pedersen C. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modeling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584–589.

10. European Medicines Agency updates patient and prescriber information for Pradaxa; 2012. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/05/ news_detail_001518.jsp&mid=WC0b01ac058004d5c1. Date of access: 09.08.2012.


For citation:


Gilyarov M.Y. THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY. Rational Pharmacotherapy in Cardiology. 2012;8(4):569-572. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-4-569-572

Views: 338


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)